Bruce N. Jacobs - Sep 3, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Financial Officer
Signature
/s/ Bruce N. Jacobs
Stock symbol
KYMR
Transactions as of
Sep 3, 2021
Transactions value $
-$621,980
Form type
4
Date filed
9/3/2021, 05:57 PM
Previous filing
Jun 4, 2021
Next filing
Nov 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise -$20.8K -10K -36.69% $2.08* 17.3K Sep 3, 2021 Direct
transaction KYMR Common Stock Sale -$510K -8.5K -49.26% $60.05 8.76K Sep 3, 2021 Direct F1, F2
transaction KYMR Common Stock Sale -$90.7K -1.5K -17.13% $60.50 7.26K Sep 3, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 -10K -4.55% $0.00 210K Sep 3, 2021 Common Stock 10K $2.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.41 to $60.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.42 to $60.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.